Quick Answer
Amylyx Pharmaceuticals, Inc. reported Total Assets of $332.65 million for the year ending 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +71.8% in Total Assets from 2024 to 2025.
- This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $274.44 million | Q2 2022: $225.24 million | Q3 2022: $181.44 million | Q1 2023: $407.96 million | Q2 2023: $453.59 million | Q3 2023: $466.58 million | Q1 2024: $417.46 million | Q2 2024: $332.16 million | Q3 2024: $250.71 million | Q1 2025: $219.68 million | Q2 2025: $194.60 million | Q3 2025: $362.74 million.
- Over the full 5 years of available data (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s Total Assets has grown by 215.0%.
- Historical annual values: Fiscal year 2025: $332.65 million | Fiscal year 2024: $193.63 million | Fiscal year 2023: $517.45 million | Fiscal year 2022: $391.45 million | Fiscal year 2021: $105.61 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: